
Innovent and Takeda Expand MarsLight-11 Trial for Lung Cancer Drug
Innovent Biologics is widening its global Phase 3 MarsLight-11 trial to include patients with non-squamous non-small cell lung cancer. The study, which evaluates the investigational drug IBI363/TAK-928, now targets both squamous and non-squamous patient populations who have previously failed to respond to chemotherapy and standard immunotherapy treatments.


























